Skip to main content

Advertisement

SpringerLink
Log in

Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Antigen-presenting cells are crucial for the induction of an antigen-specific antitumoral immune response. Deteriorations in the expression pattern of cell surface molecules important for the presentation of antigens might therefore be indicative of an impaired immune response status in cancer patients. In the present study we investigated the expression of MHC class I and class II molecules, of the costimulatory molecules CD80/B7-1 and CD86/B7-2, of the adhesion molecule CD11c, and of the marker of activation CD71 on CD14+ peripheral blood monocytes (PBMs) from 144 melanoma patients in different stages of disease and 43 healthy controls, by flow cytometric analysis. We found a decreased expression of HLA-DR (p<0.0005), HLA-DQ (p=0.006), HLA-DP (p<0.0005), and CD86/B7-2 (p=0.001) on PBMs from melanoma patients compared with healthy controls, whereas no significant difference could be detected in the expression of HLA class I antigens and CD80/B7-1. This down-regulated expression was associated with disease progression. In contrast, CD71 expression was stage-dependently increased on PBMs from melanoma patients compared with healthy controls (p=0.024). No correlation was found between the PBM surface expression pattern and age, gender, tumor load, and current mode of therapy of the patients. The observed down-regulation of HLA class II and CD86/B7-2 on melanoma patients’ PBMs might reflect an ineffective antigen-presenting function contributing to an impaired antigen-specific immune response in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1A, B
Fig. 2A, B
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. American Joint Committee on Cancer (1997) Staging manual, 5th edn. Lippincott, Philadelphia, p 143

  2. Ardavin C, Martinez del Hoyo G, Martin P, Anjuere F, Arias CF, Marin AR, Ruiz S, Parrillas V, Hernandez H (2001) Origin and differentiation of dendritic cells. Trends Immunol 22:691–700

    Article  CAS  PubMed  Google Scholar 

  3. Becker JC, Czerny C, Bröcker EB (1994) Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 6:1605–1612

    CAS  PubMed  Google Scholar 

  4. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buetnner R (1997) Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–3153

    CAS  PubMed  Google Scholar 

  5. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY (1997) The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 18:493–497

    CAS  PubMed  Google Scholar 

  6. Ditschkowski M, Kreuzfelder E, Rebmann V, Ferencik S, Majetschak M, Schmid EN, Obertacke U, Hirche H, Schade UF, Grosse-Wilde H (1999) HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 229:246–254

    PubMed  Google Scholar 

  7. Fidler IJ, Kleinerman ES (1984) Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 2:937–943

    CAS  PubMed  Google Scholar 

  8. Fidler IJ, Schroit AJ (1988) Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 948:151–173

    Article  CAS  PubMed  Google Scholar 

  9. Filaci G, Contini P, Brenci S, Lanza L, Scudeletti M, Indiveri F, Puppo F (1995) Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. Tissue Antigens 46:117–123

    CAS  PubMed  Google Scholar 

  10. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483–490

    CAS  PubMed  Google Scholar 

  11. Gebhard B, Gnant M, Schutz G, Roka S, Weigel G, Kandioler D, Taucher S, Grunberger T, Roth E, Jakesz R, Spittler A (2000) Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. Anticancer Res 20:4599–4604

    CAS  PubMed  Google Scholar 

  12. Girndt M, Sester M, Sester U, Kaul H, Kohler H (2001) Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 59:1382–1389

    Article  CAS  PubMed  Google Scholar 

  13. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189:1343–1354

    Article  CAS  PubMed  Google Scholar 

  14. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D (1995) Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31A:924–928

    Article  CAS  PubMed  Google Scholar 

  15. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607–609

    CAS  PubMed  Google Scholar 

  16. Houghton AN, Gold JS, Blachere NE (2001) Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 13:134–140

    CAS  PubMed  Google Scholar 

  17. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I–restricted tumor antigens. Science 264:961–965

    CAS  PubMed  Google Scholar 

  18. Kleinerman ES, Ceccorulli LM, Bonvini E, Zicht R, Gallin JI (1985) Lysis of tumor cells by human blood monocytes by a mechanism independent of activation of the oxidative burst. Cancer Res 45:2058–2064

    CAS  PubMed  Google Scholar 

  19. Lenschow DJ, Sperling AI, Cooke MP, Freeman G, Rhee L, Decker DC, Gray G, Nadler LM, Goodnow CC, Bluestone JA (1994) Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol 153:1990–1997

    CAS  PubMed  Google Scholar 

  20. Matsuoka T, Tabata H, Matsushita S (2001) Monocytes are differentially activated through HLA-DR, -DQ, and -DP molecules via mitogen-activated protein kinases. J Immunol 166:2202–2208

    CAS  PubMed  Google Scholar 

  21. Novellino PS, Trejo YG, Beviacqua M, Bordenave RH, Rumi LS (1999) Cisplatin containing chemotherapy influences HLA-DR expression on monocytes from cancer patients. J Exp Clin Cancer Res 18:481–484

    CAS  PubMed  Google Scholar 

  22. Novellino PS, Trejo YG, Beviacqua M, Bordenave RH, Rumi LS (2000) Regulation of HLA-DR antigen in monocytes from colorectal cancer patients by in vitro treatment with human recombinant interferon-gamma. J Investig Allergol Clin Immunol 10:90–93

    CAS  PubMed  Google Scholar 

  23. Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H (2002) Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 100:580–585

    Article  CAS  PubMed  Google Scholar 

  24. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380–384

    CAS  PubMed  Google Scholar 

  25. Roth MD, Gitlitz BJ, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, Figlin RA (2000) Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res 60:1934–1941

    CAS  PubMed  Google Scholar 

  26. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577–583

    CAS  PubMed  Google Scholar 

  27. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7:1282–1286

    CAS  PubMed  Google Scholar 

  28. van Bokhorst-de van der Schuer MA, von Blomberg-van der Flier BM, Riezebos RK, Scholten PE, Quak JJ, Snow GB, van Leeuwen PA (1998) Differences in immune status between well-nourished and malnourished head and neck cancer patients. Clin Nutr 17:107–111

    PubMed  Google Scholar 

  29. van Bokhorst-de van der S, von Blomberg-van der Flier BM, Kuik DJ, Scholten PE, Siroen MP, Snow GB, Quak JJ, van Leeuwen PA (2000) Survival of malnourished head and neck cancer patients can be predicted by human leukocyte antigen-DR expression and interleukin-6/tumor necrosis factor-alpha response of the monocyte. JPEN J Parenter Enteral Nutr 24:329–336

    PubMed  Google Scholar 

  30. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL (1996) CD80, CD86, and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 153:47–83

    PubMed  Google Scholar 

  31. Wahl SM, McCartney-Francis N, Mergenhagen SE (1989) Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today 10:258–261

    CAS  PubMed  Google Scholar 

  32. Williams MA, Withington S, Newland AC, Kelsey SM (1998) Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J Infect Dis 178:1421–1433

    CAS  PubMed  Google Scholar 

  33. Woiciechowsky C, Asadullah K, Nestler D, Schoning B, Glockner F, Docke WD, Volk HD (1998) Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation. J Neuroimmunol 84:164–171

    CAS  PubMed  Google Scholar 

  34. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431–1433

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Alexandra Stark for excellent technical assistance and Thomas Georg (Institute of Medical Biometrics, Epidemiology and Medical Informatics, University of the Saarland) for helpful support on statistical analyses.

Author information

Authors and Affiliations

  1. Skin Cancer Unit, German Cancer Research Center, Heidelberg, and Department of Dermatology, University Hospital of Mannheim, Theodor-Kutzer-Ufer 1, 68167, Mannheim, Germany

    Selma Ugurel & Dirk Schadendorf

  2. Department of Dermatology, The Saarland University Hospital, Homburg/Saar, Germany

    Dario Uhlig, Claudia Pföhler, Wolfgang Tilgen & Uwe Reinhold

Authors
  1. Selma Ugurel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dario Uhlig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudia Pföhler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wolfgang Tilgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dirk Schadendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Uwe Reinhold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Selma Ugurel.

Additional information

Both authors S. Ugurel and D. Uhlig contributed equally to this work

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ugurel, S., Uhlig, D., Pföhler, C. et al. Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother 53, 551–559 (2004). https://doi.org/10.1007/s00262-003-0489-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-003-0489-1

Keywords

Search

Navigation